Related Experiment Video
Updated: Jan 4, 2026
11:06
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
5.2K
Drug-induced liver injury
1Department of Internal Medicine, College of Medicine, Dongguk Unversity, Gyeongju, Korea.
Yeungnam University Journal of Medicine
|October 30, 2019
Summary
Drug-induced liver injury (DILI) is a serious condition that can lead to liver failure. New biomarkers and therapies are being developed to improve DILI diagnosis and treatment.
Area of Science:
- Hepatology and Pharmacology
- Biomarker Discovery
- Clinical Diagnostics
Background:
- Drug-induced liver injury (DILI), encompassing hepatotoxicity from herbal and dietary supplements, poses significant health risks, including liver failure and mortality.
- Established clinical guidelines from major gastroenterology and hepatology associations aid in DILI diagnosis and treatment.
- Current diagnostic methods like the Roussel Uclaf Causality Assessment Method have limitations in validity and reproducibility.
Purpose of the Study:
- To review the current landscape of Drug-induced liver injury (DILI) diagnosis and treatment.
- To highlight the potential of novel biomarkers for improved DILI diagnosis and prognosis prediction.
- To explore emerging therapeutic strategies and technological advancements in DILI research.
Main Methods:
- Review of recent clinical guidelines and diagnostic scoring systems for DILI.
- Analysis of ongoing research into novel biomarkers for DILI detection and outcome prediction.
- Exploration of future therapeutic avenues, including autophagy inducers and Fourth Industrial Revolution technologies.
Main Results:
- New guidelines offer improved clinical decision-making for DILI management.
- Emerging biomarkers show promise for accurate DILI diagnosis and prognosis.
- Advanced technologies and therapies are poised to revolutionize DILI research and patient care.
Conclusions:
- Accurate diagnosis and prognosis of DILI are critical due to its severe potential outcomes.
- Novel biomarkers and advanced therapeutic strategies are essential for advancing DILI management.
- The integration of new technologies holds significant promise for future DILI research and clinical application.
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
151
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
151
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
188
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
188
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
175
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
175
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
223
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
223
01:25Pharmacokinetics: Drug–Drug Interactions
304
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
304
01:16Hepatic Drug Excretion: Influencing Factors
491
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
491